Skip to main content
. Author manuscript; available in PMC: 2013 Apr 1.
Published in final edited form as: Semin Immunol. 2011 Sep 21;24(2):136–142. doi: 10.1016/j.smim.2011.08.015

Fig. 1.

Fig. 1

A schematic pathway of the steps needed to develop AMR after transplantation and the discrete activities of the various therapeutic modalities against AMR are depicted. Pathogenic antibodies are depicted in black, IVIG is depicted in gray, and antibody-based drugs are depicted in white.